Speaker
Summary
The growing interest in Targeted Alpha Therapy (TAT) has intensified worldwide research on several alpha-emitting radionuclides, including 225Ac, 213Bi, 212Pb/228Th, 211At. These isotopes offer exceptional therapeutic potential due to their short-range, high-linear-energy-transfer radiation capable of selectively eradicating tumor cells while minimizing damage to surrounding healthy tissue. Among them, 225Ac is currently one of the most promising candidates; however, its large-scale, GMP-compliant production remains challenging. While cyclotron-based routes such as 226Ra(p,2n)225Ac have been demonstrated, automated and contamination-safe systems for target preparation are still lacking. This study have confirmed the feasibility of electroplating alkaline-earth and actinide elements, paving the way for solid target development for alpha emitter generation.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
